Can a simple blood test spot recurrent brain tumors?

NCT ID NCT07398170

Recruiting now Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study aims to find out if tumor cells can be detected in the blood or spinal fluid of patients whose aggressive meningioma has come back. Researchers will take blood and spinal fluid samples from 15 adults with recurrent grade 2 or 3 meningioma. This is a proof-of-concept study, meaning it is a first step to see if the approach is possible, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that a simple blood or spinal fluid test can detect tumor cells in recurrent meningioma, potentially leading to earlier detection or monitoring.
What could go wrong: This is a very small, early proof-of-concept study with only 15 participants. It is not testing a treatment, so it may not lead to any direct patient benefit. The detection method may not be sensitive enough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma Neoplasm Recurrence, Local Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

CHU de Montpellier
RECRUITING

Montpellier, France, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.